Literature DB >> 2859972

Drug discrimination studies.

S G Holtzman.   

Abstract

Opioid agonists and agonist/antagonists comprise a heterogeneous body of compounds that can be partitioned into at least three groups on the basis of their discriminative stimulus properties in several animal species: (1) stimulus effects similar to those of morphine or fentanyl and blocked completely by low doses of antagonists, such as naloxone and naltrexone; (2) stimulus effects similar to those of ethylketocyclazocine or nalorphine and blocked by higher doses of antagonists; (3) stimulus effects similar to those N-allylnormetazocine or phencyclidine and not blocked by antagonists. This diversity of stimulus properties is consistent with other evidence that multiple populations of receptors mediate the actions of opioids. In man, drugs in group 1 produce subjective effects that are entirely morphine-like and highly reinforcing whereas drugs in groups 2 and 3 produce dysphoric and psychotomimetic subjective effects. Thus, discriminative stimulus properties of opioids appear to reflect drug actions at the neuronal level that are directly relevant to potential for abuse in man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859972     DOI: 10.1016/0376-8716(85)90061-4

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  23 in total

1.  Drug discrimination in pigeons trained to discriminate among morphine, U50488, a combination of these drugs, and saline.

Authors:  William D Wessinger; Mi Li; Donald E McMillan
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

2.  Opioid modulation of the discriminative stimulus produced by pentylenetetrazol.

Authors:  M W Emmett-Oglesby; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.

Authors:  Marcello Solinas; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

4.  Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.

Authors:  Stephen J Kohut; Takato Hiranita; Soo-Kyung Hong; Aaron L Ebbs; Valeria Tronci; Jennifer Green; Linda Garcés-Ramírez; Lauren E Chun; Maddalena Mereu; Amy H Newman; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2014-04-19       Impact factor: 13.382

5.  A within-subject assessment of the discriminative stimulus and reinforcing effects of self-administered cocaine in rhesus monkeys.

Authors:  Jennifer L Martelle; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

6.  Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.

Authors:  Torbjörn U C Järbe; Quian Liu; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

7.  Reversal of overshadowing in a drug mixture discrimination in rats.

Authors:  J A White; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

8.  Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Authors:  Neil E Paterson; Allison Fedolak; Berend Olivier; Taleen Hanania; Afshin Ghavami; Barbara Caldarone
Journal:  Pharmacol Biochem Behav       Date:  2010-03-25       Impact factor: 3.533

9.  Patterns of nicotinic receptor antagonism: nicotine discrimination studies.

Authors:  Emily M Jutkiewicz; Emily A Brooks; Adam D Kynaston; Kenner C Rice; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2011-07-05       Impact factor: 4.030

Review 10.  Drug discrimination by humans compared to nonhumans: current status and future directions.

Authors:  J B Kamien; W K Bickel; J R Hughes; S T Higgins; B J Smith
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.